As a result of the continued use of antibiotics for the treatment of bacterial disease, the world is under serious threat from “super bugs”; bacterial pathogens that have developed resistance to the point that they can no longer be controlled or effectively treated with any traditional anti-microbial. In addition, the use of harsh chemicals to treat bacterial disease is having a devastating impact on the environment, enveloping us in toxic residues.

Antibiotic-resistant bacteria continue to be a worldwide problem, causing devastating problems such as the closure of cardiac units and even entire hospitals due to outbreaks of methicillin-resistant Staphylococcus aureus (MRSA). This problem is fast developing into a crisis because there are several strains of the disease that have become resistant to all known antibiotics and have become extremely difficult to kill.

Even more concerning, the Center for Disease Control recently identified two new strains of Staph that are resistant to Vancomycin, considered the last-remaining effective treatment against this dangerous pathogen.

OmniLytics’ technology has application in many pharmaceutical opportunities. Because the technology we use is natural and safe, we are able to formulate non-toxic pharmaceuticals that solve a variety of human problems without any of the adverse side effects of traditional anti-microbials.

Our research also indicates that this technology can be used safely and effectively in ingested and topical applications, and that it can provide effective relief from a variety of bacterial ailments common to all humans.

OmniLytics’ bacteriophage products cannot only provide curative results like traditional drugs; they may also provide preventative benefits that have the ability to curtail infections both internally and topically.